Parkinson's Disease Tulip


advertisement
Reply
 
Thread Tools Display Modes
Old 12-14-2009, 03:40 PM #1
imark3000 imark3000 is offline
Member
 
Join Date: Nov 2007
Location: Calgary-Canada
Posts: 821
15 yr Member
imark3000 imark3000 is offline
Member
 
Join Date: Nov 2007
Location: Calgary-Canada
Posts: 821
15 yr Member
Default Michael J. Fox Foundation Awards $1.3 Million to Advance Potentially Disease-Modifyin

Two awardees are focused on the protein alpha-synuclein, whose clumping in the brain is a pathological hallmark of PD. Christine Bulawa, Ph.D., of FoldRx Pharmaceuticals, Inc., and colleagues have been funded by MJFF since 2007 to identify lead compounds that could prevent the death of dopamine-producing neurons due to a toxic buildup of alpha-synuclein. The group has identified a compound known as J3 that displays protective properties in a cellular PD model. Bulawa's team will now test J3 in yeast models to further examine its effects and determine the specific cellular pathways affected, fostering the development of a viable drug candidate.


Two funded teams will investigate LRRK2, a gene first linked to PD in 2004 and now believed to be the most common genetic contributor to the disease. Andrew West, Ph.D., of the University of Alabama will advance promising outcomes from an MJFF award he received in 2007 to characterize the relationship between LRRK2 overexpression and dopamine neuron death. Dr. West has created a panel of novel vector-based systems for delivering LRRK2 to the brain. His team will now deliver LRRK2 to the brain of a pre-clinical model and measure the toxic effects on dopamine neurons, with the goal of validating specifically defined aspects of LRRK2 activity as targets for Parkinson's therapeutic development.

http://www.melodika.net/index.php?op...3217&Itemid=50
MJFF fast-tracks investigations of non-Parkinson's drugs already approved by the U.S. Food and Drug Administration (FDA) (or other regulatory agency) that also show potential to benefit Parkinson's patients. Such drugs' FDA-approved status and established safety profile can accelerate their path toward clinical trials and commercialization for PD. Marina E. Emborg, MD, Ph.D., of the University of Wisconsin-Madison has been funded by MJFF since 2005 to investigate whether the FDA-approved diabetes drug pioglitazone may slow PD progression. Her team is now developing data that could be used in a future clinical trial in Parkinson's patients.


A full list of funded awards is below. Grant abstracts and researcher biosketches are available at www.michaeljfox.org.
imark3000 is offline   Reply With QuoteReply With Quote

advertisement
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off


Similar Threads
Thread Thread Starter Forum Replies Last Post
The Michael J. Fox Foundation Announces $1.5 Million in Funding to... Stitcher Parkinson's Disease 3 12-02-2009 04:36 PM
NeuroTalk Parkinson’s Group Brings About Change at Michael J. Fox Foundation lou_lou Parkinson's Disease 6 12-19-2008 12:18 PM
MJFox Foundation Awards $2.4 Million For Validation Of Nine Therapeutic Targets Stitcher Parkinson's Disease 1 07-22-2008 09:13 AM
FOX Foundation Rapid Response Awards paula_w Parkinson's Disease 0 11-05-2007 11:38 AM


All times are GMT -5. The time now is 07:42 PM.

Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise v2.7.1 (Lite) - vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.


Always consult your doctor before trying anything you read here.